Synthesis of Novel Dual Target Inhibitors of CDK12 and PARP1 and Their Antitumor Activities in HER2-Positive Breast Cancers

[Image: see text] Several anti-human epidermal growth factor receptor 2 (HER2) treatments have improved the landscape of HER2-positive breast cancer (BC) over the past few years; due to the heterogeneity of the disease itself, the drug resistance mechanisms and relapse are still the main issue in HE...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Shanshan, Jiang, Qingna, Huang, Xiuwang, Xu, Jianhua, Wu, Lixian, Liu, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10357520/
https://www.ncbi.nlm.nih.gov/pubmed/37483237
http://dx.doi.org/10.1021/acsomega.3c02912

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10357520/
https://www.ncbi.nlm.nih.gov/pubmed/37483237
http://dx.doi.org/10.1021/acsomega.3c02912

Ejemplares similares